Femasys is trading 11.3% down today at $3.29 as investors lock in gains following a period of sharp price appreciation and recent volatility.
- The decline appears driven by profit-taking rather than fundamental shifts, with no new company filings, earnings releases, or major headlines reported today.
- The stock is notably lagging a broader rally in the biotech sector, suggesting the move is a technical correction rather than a change in company outlook.